TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00001066
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001066
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06393751
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06393751
Drug: Tolinapant
Normalized name: Tolinapant
DrugBank: Tolinapant (DB16160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04994977
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given at 0.5 mg/ml.
Study: NCT04994977
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given at 5 mg/ml.
Study: NCT04994977
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given at 0.2 mg/ml.
Study: NCT05857748
Drug: lifitegrast
Normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient newly started on medication will be followed for 6 months
Study: NCT06650384
Drug: Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin
Normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day
Study: NCT06251115
Drug: QY-1-T
Normalized name: 1-T
DrugBank: 1-Testosterone (DB01481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QY-1-T is a TCR-T drug targeting HBV-related HCC
Study: NCT05442736
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: studying the effect of nanoparticles in controlling the release of the drug in addition to in situ gel
Study: NCT04470024
Drug: INCAGN01876
Normalized name: Incagn01876
DrugBank: Ragifilimab (DB18853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: agonistic antihuman GITR mAb
Study: NCT05291650
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 2.0 ml drug including 1.5 ml saline and 0.5 ml lidocaine will be injected into the infrapatellar fat pad for the placebo group.
Study: NCT05291650
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After completing the process of infrapatellar fat pad injection, the participants in both groups will receive 2.5 ml hyaluronic acid suspension injection through the suprapatellar bursa into the intra-articular space.
Study: NCT04670796
Drug: HLX02
Normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subject receive one dose of HLX02
Study: NCT04670796
Drug: EU-sourced Trastuzumab (Herceptin®)
Normalized name: trastuzumab Injection [Herceptin]
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subject receive one dose of EU-sourced Trastuzumab (Herceptin®)
Study: NCT04670796
Drug: US-licensed Trastuzumab (Herceptin®)
Normalized name: trastuzumab Injection [Herceptin]
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subject receive one dose of US-licensed Trastuzumab (Herceptin®)
Study: NCT06173466
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal bupivacaine 133mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
Study: NCT06173466
Drug: Bupivacaine Hydrochloride combined with dexamethasone
Normalized name: bupivacaine hydrochloride / epinephrine Cartridge [Marcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard bupivacaine combined with dexamethasone 4mg was injected to paravertebral intervals of right T7/8, T8/9, T9//10, T10/11 via ultrasound-guided TPVB
Study: NCT05790447
Drug: Thymalfasin
Normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: loading dose with thymalfasin based on the amounts of T lymphocyte
Study: NCT05790447
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection daily for 7 consecutive days
Study: NCT05863455
Drug: control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ntravenous injection of an equivalent volume of saline before radial artery cannulation.
Study: NCT05160415
Drug: Sevasemten
Normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose
Study: NCT05348811
Drug: HAIC combined with donafenib and sintilimab
Normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC- GEMOX regimen, gemcitabine 1000 mg/m2, oxaliplatin 85mg/m2 (if the maximum tumor diameter \> 10cm, the dose is 130mg/m2), the first day of each cycle (D1), Q3W. The maximum of 6 times.~Sintilimab will be given on the first day of each cycle (D1). 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.The longest treatment time is 24 months.~Donafenib was taken orally at 0.2 bid on an empty stomach (1 hour before or \> 2 hours after meal) in the morning and evening of each administration day, with an interval of about 12 hours. Donafenib treatment is initiated within 1 to 3 days of each HAIC treatment until toxicity is intolerable, the investigator determines disease progression, death, informed consent is withdrawn, new antitumor therapy is initiated, or treatment is discontinued for any other reason specified in the protocol.
Study: NCT06127238
Drug: ST-1898 tablets
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplied as 5 mg and 40 mg tablets
Study: NCT05644873
Drug: magnesium sulfate group
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The magnesium group received a bolus of 20 mg/kg of magnesium sulfate in 100 mL of saline for 15 minutes prior to induction, followed by a continuous infusion of 20 mg/kg/hr until skin closure.
Study: NCT06513208
Drug: Ketorolac Tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Ketorolac 15mg every 6 hours, x 4 doses
Study: NCT00000628
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05714007
Drug: Ferric derisomaltose
Normalized name: ferric derisomaltose
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose ferric derisomaltose
Study: NCT05714007
Drug: Ferrous succinate
Normalized name: Ferrous succinate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of 100 mg iron (ferrous succinate) tid postoperatively
Study: NCT05631249
Drug: Sotorasib 120Mg Tab
Normalized name: SOTORASIB 120MG TAB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily sotorasib treatment until progression, unacceptable toxicity, death, or lost to follow-up
Study: NCT05692999
Drug: Pembrolizumab 200 mg Q6W
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg Q6W
Study: NCT05692999
Drug: Pemetrexed 500 mg/m^2 Q3W
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m\^2 Q3W
Study: NCT05692999
Drug: Pembrolizumab 200 mg Q3W or 400 mg Q6W
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg Q3W or 400 mg Q6W
Study: NCT04850599
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04850599
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05231980
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline is a methylxanthine derivative which acts as a vasodilator by increasing blood flow to tissues, inhibits inflammatory responses, and reduces blood viscosity by impeding platelet aggregation
Study: NCT05231980
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: is a medication used to treat infertility in women who do not ovulate
Study: NCT05296161
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Personalized B cell tailored ocrelizumab treatment
Study: NCT04603183
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive abemaciclib 150 mg orally twice daily (BID) (300 mg daily, administered as six 50 mg tablets) during each 28 day cycle combined with either letrozole or fulvestrant.
Study: NCT04603183
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 90 mg/m² infused over 1 hour on Days 1, 8, and 15 of the 28 day cycle, with at least a 6-day time span between separated doses.
Study: NCT04603183
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 2.5 mg letrozole, orally administered and taken daily during each 28-day cycle combined with abemaciclib.
Study: NCT04603183
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive 500 mg fulvestrant, by intramuscular \[IM\] administration on Days 1 and 15 (±3 days) of the first treatment cycle and Day 1 of each cycle thereafter combined with abemaciclib.
Study: NCT00002414
Drug: CPI-1189
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04825743
Drug: zalunfiban
Normalized name: Zalunfiban
DrugBank: Zalunfiban (DB18766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: zalunfiban is a novel small molecule inhibitor of the platelet αIIbβ3 receptor specifically designed for first medical contact therapy of ST-elevation myocardial infarction (STEMI).
Study: NCT04336826
Drug: Ataluren
Normalized name: Ataluren
DrugBank: Ataluren (DB05016)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Ataluren will be administered as per the dose and schedule specified in the arm.
Study: NCT05004415
Drug: AT-527 (R07496998)
Normalized name: AT-III
DrugBank: AT-527 (DB16451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive a single radiolabeled dose of 550 mg AT-527.
Study: NCT06344091
Drug: Bupivacaine Liposome Injection
Normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
Study: NCT03906357
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00399022
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05248841
Drug: HEC-Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.
Study: NCT05229614
Drug: Immunotherapy (Pembrolizumab)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only cancer patients under treatment with pembrolizumab monotherapy, administered within clinical practice and according to the Italian Drug Regulatory Agency (Agenzia Italiana del Farmaco, AIFA), will be enrolled.
Study: NCT05456256
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed: 500 mg/m2 by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. After completion of the 4 to 6 cycles, patients will have the option to continue pemetrexed maintenance therapy until disease progression, unacceptable toxicity, or patient preference/physician discretion. The number of treatment cycles will be determined by PI discretion.
Study: NCT05456256
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin: area under the concentration-time curve 5 mg/mL per minute (AUC5) by intravenous (IV) infusion over 30 minutes, administered every 21 days for a total of 4 to 6 treatment cycles. The number of treatment cycles will be determined by PI discretion.
Study: NCT04696146
Drug: Berinert
Normalized name: Berinert
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarenal dose of 500 U of Berinert
Study: NCT06270407
Drug: Tranexamic Acid 100 MG/ML
Normalized name: tranexamic acid 100 MG/ML
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid
Study: NCT06270407
Drug: 0.9%sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
Study: NCT06135155
Drug: PEG-rhGH with new preparation
Normalized name: RhGH-PEG
DrugBank: Lonapegsomatropin (DB16220)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single subcutaneous injection of PEG-rhGH with new preparation
Study: NCT05785208
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib will be administered at a dose of 80 mg daily until disease progression
Study: NCT06135155
Drug: PEG-rhGH with present preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study: NCT05574179
Drug: Dexmedetomidine injection
Normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inj precedex 200mcg in 1ml given in stat doses
Study: NCT05574179
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inj.midazolam 5mg/5ml given in stat doses
Study: NCT06450886
Drug: Ulviprubart (ABC008)
Normalized name: Ulviprubart
DrugBank: Ulviprubart (DB18281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.
Study: NCT06226610
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: injection every two weeks while on study
Study: NCT04976777
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 0.7 mg in a solid polymer drug delivery system
Study: NCT05973903
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Lenvatinib 20 mg once daily
Study: NCT05973903
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous pembrolizumab 200 mg every three weeks
Study: NCT04551495
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles
Study: NCT04551495
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles
Study: NCT04551495
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
Study: NCT04795531
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study: NCT04795531
Drug: Placebo insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study: NCT04795531
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study: NCT04795531
Drug: Placebo insulin degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study: NCT05544721
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
Study: NCT05359237
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV per standard of care
Study: NCT05193565
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally, once-daily in the morning - Check the blood concentration of Sirolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~8ng/mL
Study: NCT05193565
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Up to 1g BID(total 2g daily), PO
Study: NCT04704622
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine intranasal injection,2 mg/kg, once, 30 min preoperative
Study: NCT04704622
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam intranasal injection,0.2mg/kg, once, 30 min preoperative
Study: NCT04704622
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine intranasal injection,1 μg/kg, once, 30 min preoperative
Study: NCT05871957
Drug: Vitamin D Drops
Normalized name: Floriva with 0.25mg Fluoride and Vitamin D Drops
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement 2000IU of vitamin D, no matter the brand or manufacturer for 1 month.
Study: NCT06520007
Drug: Doxycyclin
Normalized name: Doxycyclin
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The drug has been prescribed, as in normal clinical practice, with the National Healthcare System. Patients have been fully informed about interactions, toxicity and posology schedule.
Study: NCT00172341
Drug: Staloral TM
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05604742
Drug: Belimumab (Benlysta)
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab will be administered intravenously every 2 weeks for 3 cycles and then every 4 weeks for a total of 5 cycles
Study: NCT04220008
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04220008
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04220008
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04220008
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04220008
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04220008
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05325528
Drug: Tislelizumab in Combination with Oxaliplatin and Tegafur
Normalized name: Tislelizumab
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 cycles of Tislelizumab plus SOX regimen every 21 days
Study: NCT05176158
Drug: Dexketoprofen 25 MG
Normalized name: dexketoprofen 25 MG
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill at morning
Study: NCT06490328
Drug: DKF-MA102
Normalized name: DKFZ-PSMA-11 Ga-68
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered twice at 12-week intervals